Cancer remains one of the most common diseases that leads to patient death. Because of the high degree of heterogeneity in the disease, patients with the same tissue cancer may display a range of phenotypes. Even minor lesion can now be identified owing to advancements in imaging techniques, but more research is needed to understand their genetic causes. Thus, it is essential to efficiently identify specific indicators, often referred to as biomarkers, that would allow for early cancer diagnosis, evaluation of the degree of disease development, monitoring of treatment effectiveness, or discovery of new therapeutic targets. The continuous development of molecular techniques in the field of genomics, proteomics, metabolomics, and transcriptomics allows the identification of new biomarkers that can more precisely describe the relationship between the tumor cell phenotype and patient prognosis or select appropriate targeted therapy that is more beneficial for an individual patient.

This Special Issue welcomes contributions that improve our understanding of the novel molecular biomarkers in solid tumors. Potential areas of interest may include, but are not limited to:
• In vitro studies
• Novel clinical studies
• Bioinformatic investigations
• Multi-omics methods.
• Personalized medicine
• Target therapy

For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: abp@frontierspartnerships.org.

Keywords: genomics, proteomics, metabolomics, transcriptomics, sequencing, oncology